Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement‑positive lung adenocarcinoma: A case report

Takakuwa,Osamu; Oguri,Tetsuya; Yokoyama,Midori; Hijikata,Hisatoshi; Uemura,Takehiro; Ohkubo,Hirotsugu; Maeno,Ken; Niimi,Akio

doi:10.3892/mco.2013.188

January-February 2014 Volume 2 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

January-February 2014 Volume 2 Issue 1

Full Size Image

Case Report

Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement‑positive lung adenocarcinoma: A case report

Authors:
- Osamu Takakuwa
- Tetsuya Oguri
- Midori Yokoyama
- Hisatoshi Hijikata
- Takehiro Uemura
- Hirotsugu Ohkubo
- Ken Maeno
- Akio Niimi
View Affiliations / Copyright

Affiliations: Department of Medical Oncology and Immunology, Nagoya City University, Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan
Pages: 121-123
|
Published online on: September 20, 2013

https://doi.org/10.3892/mco.2013.188
Expand metrics +

Abstract

Non‑small‑cell lung cancer (NSCLC) is the most commonly diagnosed type of cancer and is a leading cause of cancer‑related mortality worldwide. treatment is currently focused on individualization according to the molecular profile of the disease. Here we present the case of a 41‑year‑old patient who presented with multiple pulmonary nodules, a left pleural effusion and an ovarian tumor. Adenocarcinoma of the lung was diagnosed from pathological examination of the pleural effusion and the surgically resected ovarian tumor, and chemotherapy was initiated. Relapse was experienced following third‑line chemotherapy with pemetrexed and anaplastic lymphoma kinase (ALK)‑positive adenocarcinoma was diagnosed using a specimen from the resected ovarian tumor. Subsequently, crizotinib therapy was initiated. Eight days later the patient developed severe nausea and vomiting and esophagitis was diagnosed by gastrointestinal endoscopic examination. Following the interruption of crizotinib treatment by treatment with a proton pump inhibitor (PPI), crizotinib treatment was re‑initiated and was effective for a minimum of 6 months. Clinicians should be aware that treatment with crizotinib may result in severe esophagitis.

View Figures

View References

1.	Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 448:561–566. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
4.	Camidge DR, Bang YJ, Kwak EL, et al: Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13:1011–1019. 2012. View Article : Google Scholar : PubMed/NCBI
5.	Shaw A, Yeap B, Solomon B, et al: Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls. J Clin Oncol. 29(Suppl): abs.75072011.
6.	Shaw A, Kim D, Nakagawa K, et al: Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC) (PROFILE 1007). Ann Oncol. 23(Suppl 10): abs. LBA1_PR. 2012.
7.	Pfizer: Crizotinib adverse drug reactions reported from the clinical trials (PROFILE 1001 study and PROFILE 1005 study).
8.	Pfizer: Xalkori adverse drug reactions reported from the post-marketing surveillance in Japan.
9.	Thunnissen E, Bubendorf L, Dietel M, et al: EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 461:245–257. 2012. View Article : Google Scholar : PubMed/NCBI
10.	Takeuchi K, Choi YL, Togashi Y, et al: F5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 15:3143–3149. 2009. View Article : Google Scholar : PubMed/NCBI
11.	Mino-Kenudson M, Chirieac LR, Law K, et al: A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res. 16:1561–1571. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Kalikaki A, Koutsopoulos A, Trypaki M, et al: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer. 99:923–929. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Camidge DR, Kono SA, Lu X, et al: Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol. 6:774–780. 2011. View Article : Google Scholar : PubMed/NCBI
14.	Camidge DR and Doebele RC: Treating ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol. 9:268–277. 2012. View Article : Google Scholar : PubMed/NCBI
15.	Lee JO, Kim TM, Lee SH, et al: Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol. 6:1474–1480. 2011. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Esophagitis resulting from treatment with crizotinib for anaplastic lymphoma kinase rearrangement‑positive lung adenocarcinoma: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles